Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Published:2020-04-05 Issue:9 Volume:86 Page:1807-1818
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Rolfo Christian¹^ORCID,Isambert Nicolas²,Italiano Antoine³,Molife L. Rhoda⁴,Schellens Jan H.M.⁵⁶,Blay Jean‐Yves⁷,Decaens Thomas⁸,Kristeleit Rebecca⁹,Rosmorduc Olivier¹⁰,Demlova Regina¹¹,Lee Myung‐Ah¹²,Ravaud Alain¹³,Kopeckova Katerina¹⁴,Learoyd Maria¹⁵,Bannister Wendy¹⁶,Locker Gershon¹⁷,Vos‐Geelen Judith¹⁸

Affiliation:

1. Marlene and Stewart Greenebaum Comprehensive Cancer Center, Experimental Therapeutics Program University of Maryland School of Medicine Baltimore Maryland USA

2. Centre Georges François Leclerc Dijon France

3. Institut Bergonié, Gironde France

4. *Royal Marsden Hospital London UK

5. The Netherlands Cancer Institute Amsterdam The Netherlands

6. Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The Netherlands

7. Centre Léon Bérard Lyon France

8. Department of hepato‐gastroenterology, Université Grenoble‐Alpes, CHU Grenoble‐Alpes Institute for Advanced Biosciences Grenoble France

9. The Netherlands Cancer Institute, Amsterdam and Utrecht University Utrecht The Netherlands

10. APHP, Hôpital La Pitié Salpêtrière Service d'Hépato‐Gastroentérologie Paris France

11. Faculty of Medicine, Department of Pharmacology Masaryk Memorial Cancer Institute, Masaryk Univerzity Brno Czech Republic

12. The Catholic University of Korea, Seoul St. Mary's Hospital Seoul South Korea

13. Hôpital Saint André Bordeaux University Hospital Bordeaux France

14. University Hospital in Motol, Charles University Prague Czech Republic

15. AstraZeneca Cambridge UK

16. Phastar London UK

17. AstraZeneca Gaithersburg MD USA

18. Department of Internal Medicine, Division of Medical Oncology, GROW—School for Oncology and Developmental Biology Maastricht University Medical Center Maastricht The Netherlands

Funder

AstraZeneca

Merck Sharp and Dohme

Merck

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14283

Reference29 articles.

1. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

2. European Medicines Agency.Lynparza (olaparib): An overview of Lynparza and why it is authorised in the EU.2019. Available at:https://www.ema.europa.eu/en/documents/overview/lynparza-epar-medicine-overview_en.pdf.

3. European Medicines Agency.Lynparza summary of product characteristics.2014. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf

4. FDA.Lynparza prescribing information.2014. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf.

5. European Medicines Agency.CHMP assessment report on extension of marketing authorisation grouped with a variation: Lynparza.2018. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/003726/WC500249582.pdf

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?;Expert Opinion on Investigational Drugs;2024-08-20

2. Cannabinoids and triple-negative breast cancer treatment;Frontiers in Immunology;2024-08-08

3. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics;Seminars in Oncology;2023-10

4. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment;Scientific Reports;2023-09-25

5. Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Olaparib When Co-administered with CYP3A4 Modulators and in Patients with Hepatic/Renal Impairment;2023-06-09